Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 160

Similar articles for PubMed (Select 18344568)

1.

Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group.

N Engl J Med. 2008 Mar 20;358(12):1215-28. doi: 10.1056/NEJMoa070812. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530.

2.

Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.

Schwartz LB, Sheikh J, Singh A.

Curr Med Res Opin. 2010 Aug;26(8):1933-46. doi: 10.1185/03007995.2010.493132. Review.

PMID:
20565230
3.

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.

Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM.

N Engl J Med. 2009 Mar 5;360(10):985-93. doi: 10.1056/NEJMoa0805435.

5.

Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.

Roufosse F, de Lavareille A, Schandené L, Cogan E, Georgelas A, Wagner L, Xi L, Raffeld M, Goldman M, Gleich GJ, Klion A.

J Allergy Clin Immunol. 2010 Oct;126(4):828-835.e3. doi: 10.1016/j.jaci.2010.06.049.

6.

A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.

Busse WW, Ring J, Huss-Marp J, Kahn JE.

J Allergy Clin Immunol. 2010 Apr;125(4):803-13. doi: 10.1016/j.jaci.2009.11.048. Review.

PMID:
20371394
7.

Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.

Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith DA, Patel J, Byrne M, Simon HU.

Gut. 2010 Jan;59(1):21-30. doi: 10.1136/gut.2009.178558. Epub .

PMID:
19828470
8.

Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics.

Dahabreh IJ, Giannouli S, Zoi C, Zoi K, Voulgarelis M, Moutsopoulos HM.

Medicine (Baltimore). 2007 Nov;86(6):344-54.

PMID:
18004179
9.

Hypereosinophilic syndrome and mepolizumab.

Verzegnassi F.

N Engl J Med. 2008 Jun 26;358(26):2838; author reply 2839-40. No abstract available.

PMID:
18584819
10.

Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.

Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD.

J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5. doi: 10.1016/j.jaci.2012.07.055. Epub 2012 Oct 4.

11.

Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.

Helbig G, Moskwa A, Hus M, Piszcz J, Swiderska A, Urbanowicz A, Całbecka M, Gajkowska J, Seferyńska I, Hałasz M, Woszczyk D, Markiewicz M, Krzemień S.

Hematol Oncol. 2010 Jun;28(2):93-7. doi: 10.1002/hon.919.

PMID:
19728396
12.

[New insights into hypereosinophilic syndromes].

Bletry O, Kahn JE, Ackermann F, Charles P, Legrand F.

Bull Acad Natl Med. 2010 Mar;194(3):547-59; discussion 559-60. French.

PMID:
21171248
13.

Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.

Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, Beck LA, Boyce JA, Filipovich AH, Villanueva JM, Sutton SA, Assa'ad AH, Rothenberg ME.

J Allergy Clin Immunol. 2004 Jan;113(1):115-9. Epub 2003 Dec 12.

PMID:
14699394
14.

Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.

Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD.

J Allergy Clin Immunol. 2009 Dec;124(6):1319-25.e3. doi: 10.1016/j.jaci.2009.09.022. Epub .

15.
16.

The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.

La Starza R, Specchia G, Cuneo A, Beacci D, Nozzoli C, Luciano L, Aventin A, Sambani C, Testoni N, Foppoli M, Invernizzi R, Marynen P, Martelli MF, Mecucci C.

Haematologica. 2005 May;90(5):596-601.

18.

Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.

Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, Hijnen DJ, Plötz S, Knol EF, Kapp A, Bruijnzeel-Koomen CA, Ring J, de Bruin-Weller MS.

Allergy. 2005 May;60(5):693-6.

PMID:
15813818
19.

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.

Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G.

Haematologica. 2007 Sep;92(9):1173-9. Epub 2007 Aug 1.

20.

Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants.

Roufosse F, Goldman M, Cogan E.

Semin Respir Crit Care Med. 2006 Apr;27(2):158-70. Review.

PMID:
16612767
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk